Jing-Chen Ma1, Zhi-Wei Wu1, Hai-Song Zhou2, Zhao Gao1, Zhi-Yong Hao2, Fei Jin1, Yan-Hong Zhang2, Min-Jie Li1, Feng Wang3, Qi Li1, Sheng-Li Bi3, Yu-Liang Zhao1. 1. Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China. 2. Institute for Hepatitis, Zhengding County Center for Disease Control and Prevention, Zhengding, People's Republic of China. 3. Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
Abstract
Background: To assess the long-term protection conferred by plasma-derived hepatitis B vaccine at 20-31y after primary immunization during infancy in Chinese rural community.Method: Participants born between 1986 and 1996, who received a full course of primary vaccination with plasma-derived hepatitis B vaccine and had no experience with booster vaccination were enrolled. An epidemiological investigation was performed, and blood samples were collected to detect hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc). The positive rate of HBsAg, anti-HBs, and anti-HBc were calculated to evaluate the long-term protection of the plasma-derived hepatitis B vaccine. Results: A total of 949 participants were enrolled in the final analysis. Six subjects were detected to be HBsAg-positive, resulting in a HBsAg carrier rate of 0.63% (6/949). A total of 468 (52.41%) participants maintained a level of anti-HBs antibody ≥10 mIU/mL, with a GMC of 112.20 mIU/mL (95%CI: 97.72 ~ 128.82 mIU/mL). A significant downtrend was observed in the anti-HBs positive rate (P < .001). The average anti-HBc positive rate was 5.90% (56/949), increased with prolongation of immunization (P < .001).Conclusions: The plasma-derived hepatitis B vaccine maintained satisfactory protection at 20-31 y after primary immunization. These results indicate that a booster dose is not necessary. Further studies on the immune memory induced by the plasma-derived hepatitis B vaccine are needed.
Background: To assess the long-term protection conferred by plasma-derived hepatitis B vaccine at 20-31y after primary immunization during infancy in Chinese rural community.Method: Participants born between 1986 and 1996, who received a full course of primary vaccination with plasma-derived hepatitis B vaccine and had no experience with booster vaccination were enrolled. An epidemiological investigation was performed, and blood samples were collected to detect hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc). The positive rate of HBsAg, anti-HBs, and anti-HBc were calculated to evaluate the long-term protection of the plasma-derived hepatitis B vaccine. Results: A total of 949 participants were enrolled in the final analysis. Six subjects were detected to be HBsAg-positive, resulting in a HBsAg carrier rate of 0.63% (6/949). A total of 468 (52.41%) participants maintained a level of anti-HBs antibody ≥10 mIU/mL, with a GMC of 112.20 mIU/mL (95%CI: 97.72 ~ 128.82 mIU/mL). A significant downtrend was observed in the anti-HBs positive rate (P < .001). The average anti-HBc positive rate was 5.90% (56/949), increased with prolongation of immunization (P < .001).Conclusions: The plasma-derived hepatitis B vaccine maintained satisfactory protection at 20-31 y after primary immunization. These results indicate that a booster dose is not necessary. Further studies on the immune memory induced by the plasma-derived hepatitis B vaccine are needed.
Entities:
Keywords:
Hepatitis B virus; long-term protection; primary vaccination; vaccine
Authors: Brian J McMahon; Catherine M Dentinger; Dana Bruden; Carolyn Zanis; Helen Peters; Debbie Hurlburt; Lisa Bulkow; Anthony E Fiore; Beth P Bell; Thomas W Hennessy Journal: J Infect Dis Date: 2009-11-01 Impact factor: 5.226
Authors: Stephanie R Bialek; William A Bower; Ryan Novak; Louisa Helgenberger; Steven B Auerbach; Ian T Williams; Beth P Bell Journal: Pediatr Infect Dis J Date: 2008-10 Impact factor: 2.129
Authors: Mohammed A AlAteeq; Latifa M AlEnazi; Modhi S AlShammari; Essa E AlAnazi; Fadel H Al-Hababi; Abdulrahman M Alateeq Journal: Cureus Date: 2022-01-15